SAN DIEGO--(BUSINESS WIRE)--Celladon Corporation today announced that its SERCA2a programs for the treatment of patients with acute and chronic heart failure have been chosen by Windhover and an independent expert panel as one of the top 10 most interesting cardiovascular projects available for partnering. Projects available for partnering include MYDICAR®, a genetically targeted enzyme-replacement therapy intended to restore levels of SERCA2a and in phase 2 development; and CDN small molecule compounds that activate SERCA2a, as intravenous or oral drugs, for the treatment of acute and chronic heart failure. SERCA2a is a protein that is vital in the proper functioning of the heart.
